Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Valeritas Holdings Inc. VLRXQ

Healthcare

Valeritas Holdings Inc is a commercial-stage medical technology company. It is engaged in the business of improving health and simplifying life for diabetic patients by developing and commercializing innovative technologies. The company designed its first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, that supports the patients with Type 2 diabetes who need insulin... see more

Add To Watchlist

Recent & Breaking News (OTCPK:VLRXQ)

Preclinical Study Shows Valeritas Proprietary h-Patch(TM) Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine

GlobeNewswire August 5, 2019

Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch(TM) Wearable Device in Preclinical Study

GlobeNewswire July 30, 2019

Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019

GlobeNewswire July 22, 2019

Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population

GlobeNewswire July 8, 2019

Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device

GlobeNewswire June 27, 2019

Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold

GlobeNewswire June 24, 2019

Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery

GlobeNewswire June 10, 2019

Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire May 31, 2019

Valeritas to Participate in the American Diabetes Association's 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance

GlobeNewswire May 29, 2019

American Diabetes Association Includes "Disposable Patch-Like Device," such as V-Go® from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019

GlobeNewswire May 28, 2019

Valeritas' V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population

GlobeNewswire May 22, 2019

Valeritas Announces Reverse Stock Split

GlobeNewswire May 17, 2019

Valeritas Exhibits at Taking Control of Your Diabetes Conferences

GlobeNewswire May 13, 2019

Valeritas Announces First Quarter 2019 Financial Results and Updates Full Year 2019 Revenue Guidance

GlobeNewswire May 9, 2019

Valeritas Expects First Quarter Revenue of $6.4 million

GlobeNewswire May 2, 2019

Valeritas to Present at Upcoming Investor Conferences

GlobeNewswire April 29, 2019

Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.5 and Total Daily Insulin Dosage by 14%

GlobeNewswire April 26, 2019

Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019

GlobeNewswire April 22, 2019

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment

GlobeNewswire April 8, 2019

Valeritas partners with the American Association of Diabetes Educators (AADE)

GlobeNewswire April 1, 2019